98%
921
2 minutes
20
The T300A substitution in ATG16L1 associated with Crohn's disease impairs autophagy, yet up to 50% of humans are heterozygous for this allele. Here, we demonstrate that heterozygosity for the analogous substitution in mice (Atg16L1), but not homozygosity, protects against lethal Salmonella enterica Typhimurium infection. One copy of Atg16L1 was sufficient to enhance cytokine production through inflammasome activation, which was necessary for protection. In contrast, two copies of Atg16L1 inhibited the autophagy-related process of LC3-associated phagocytosis (LAP) and increased susceptibility. Macrophages from human donors heterozygous for ATG16L1 displayed elevated inflammasome activation while homozygosity impaired LAP, similar to mice. These results clarify how the T300A substitution impacts ATG16L1 function and suggest it can be beneficial to heterozygous carriers, providing an explanation for its prevalence within the human population.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158642 | PMC |
http://dx.doi.org/10.1016/j.immuni.2025.04.023 | DOI Listing |
Eur J Radiol
August 2025
Unità Operativa di Radiologia, ASST Fatebenefratelli Sacco, L. Sacco University Hospital, Milan, Italy. Electronic address:
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and Ulcerative Colitis (UC), is characterized by chronic inflammation of the gastrointestinal tract, and its long-standing course significantly elevates the risk of colorectal cancer (CRC), primarily arising from dysplastic lesions. While regular surveillance by colonoscopy is well established for UC patients, guidelines for CD remain uncertain. Computed Tomographic Colonography (CTC) offers a minimally invasive alternative for evaluating the colon, particularly in cases where colonoscopy is incomplete or contraindicated.
View Article and Find Full Text PDFAliment Pharmacol Ther
September 2025
Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
Inflamm Bowel Dis
September 2025
Pediatric Gastroenterology, Hepatology and Cystic Fibrosis Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Background: The effect of sarcopenia on clinical outcomes in children with Crohn's disease (CD) is unknown. We investigated whether sarcopenia at the diagnosis impacts the outcomes of children with CD.
Methods: This was a retrospective, single-center, case-control study of newly diagnosed children with CD undergoing magnetic resonance (MR) within 1 month from the diagnosis, from 2011 to 2022.
Inflamm Bowel Dis
September 2025
Division of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, United States.
Background: In patients with inflammatory bowel disease (IBD), social determinants of health contribute to health inequalities. We aimed to compare patients with IBD treated at a private nonprofit vs public hospital in New York City.
Methods: We performed a retrospective study of adult patients with Crohn's disease or ulcerative colitis with established IBD care.
J Crohns Colitis
September 2025
Laboratory for Complex Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.
Background And Aims: Inflammatory bowel disease (IBD) often affects multiple relatives, pointing towards shared genetic and/or environmental factors. This study evaluates the importance of known IBD risk variants, and of genetic determinants of smoking in such multiplex families.
Methods: We studied 65 IBD multiplex families, comprising 146 Crohn's disease [CD], 33 ulcerative colitis [UC], and 111 unaffected relatives.